Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) Signs LOI to Advance ONC010 Development, Appoints VP of Corporate Finance 

Austin, Texas, June 8th, 2026, FinanceWire

This article has been disseminated on behalf of  Onco-Innovations Limited  and may include paid advertising. 

Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ)  announced it has entered into a non-binding letter of intent with Nanosoft Polymers as an initial step toward negotiating a services agreement supporting development of its exclusively licensed PNKP inhibitor technology, ONC010. The proposed collaboration would focus on polymer process development, analytical characterization, formulation optimization and manufacturing planning activities designed to support future clinical and regulatory development of the oncology candidate. 

The company also appointed Dave Antony as vice president of corporate finance. Antony brings more than 35 years of experience in financial planning, reporting, corporate governance and public company advisory services, including leadership roles with TSX Venture Exchange advisory committees. Onco said his background in capital markets and corporate finance is expected to support the company’s oncology-focused growth strategy and ongoing engagement with investors and other stakeholders.

To view the full press release, visit  https://ibn.fm/JB4rY

About Onco-Innovations Limited

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The Company has secured an exclusive worldwide license to patented technology that targets solid tumours.

For more information go to  https://oncoinnovations.com/

About BioMedWire

BioMedWire  (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the  Dynamic Brand Portfolio @  IBN that delivers: (1) access to a vast network of wire solutions via  InvestorWire  to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and  editorial syndication to 5,000+ outlets ; (3) enhanced  press release enhancement  to ensure maximum impact; (4)  social media distribution  via IBN to millions of social media followers; and (5) a full array of tailored  corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit  https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:  https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by  IBN

Contact